GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc. has announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naïve acute myeloid leukemia.